Announcement on behalf of OBIGEN that TFDA clears OBI-858’s IND application for repeat-dose Phase II safety study

Date of occurrence of the event:2025/01/22 New drug name or code: OBI-858 Novel Botulinum Neurotoxin Indication: OBI-858, an in-house developed novel botulinum neurotoxin (BoNT) product, is planned for aesthetic and therapeutic uses. Patents for its special molecular weight have been granted in Taiwan, Australia, New Zealand, Japan and Russia. Clinical trial information: https://e-sub.fda.gov.tw/ClinicalTrialInfo/case-search/OBI-858-002 Planned development […]